Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06160752
Other study ID # TYR200-101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date November 22, 2023
Est. completion date September 2027

Study information

Verified date March 2024
Source Tyra Biosciences, Inc
Contact Jennifer M Davis
Phone (619)728-4805
Email TyraClinicalTrials@tyra.bio
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.


Description:

This is a single arm, multi-part, phase 1 clinical trial studying TYRA-200, a novel, potent fibroblast growth factor receptor (FGFR) 1/2/3 tyrosine kinase inhibitor, in unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors with activating alterations in FGFR2. Part A is a dose escalation study in participants with any advanced solid tumor with FGFR/FGF pathway alterations who have exhausted approved standard therapies. Part A will evaluate the safety, tolerability, and PK of TYRA-200 to determine the optimal and maximum tolerated dose (MTD). Part B will evaluate the preliminary antitumor activity of TYRA-200 in participants with unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma who have previously received an FGFR inhibitor and have FGFR2 kinase-domain mutations resistant to other FGFR inhibitors.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date September 2027
Est. primary completion date September 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Phase 1 Part A - Men and women 18 years of age or older. - Eastern Cooperative Oncology Group (ECOG) performance status of =1. - Any histologically confirmed advanced solid tumor with FGFR/FGF pathway alterations including FGFR gene mutations, fusions, and amplifications, as well as gene amplifications of FGFR ligands, who have exhausted or refused approved standard therapies. - Evaluable disease according to RECIST v1.1. Phase 1 Part B - Men and women 18 years of age or older. - Eastern Cooperative Oncology Group (ECOG) performance status of =1. - Histologically confirmed locally advanced/metastatic intrahepatic cholangiocarcinoma with a previously identified FGFR2 gene mutation or rearrangement. - Must have received a prior FGFR inhibitor. Participants may have received more than 1 prior FGFR inhibitor. - Presence of an FGFR2 kinase domain mutation that confers resistance to previous/other FGFR inhibitors; resistance mutations should be identified by a US Food and Drug Administration authorized/approved companion diagnostic or a Clinical Laboratory Improvement Amendments (CLIA) validated local test performed in a certified laboratory. - At least 1 measurable lesion by RECIST v1.1. Exclusion Criteria: - Discontinued a prior anti-FGFR therapy due to significant toxicity, defined as hepatotoxicity =Grade 3 or any Grade 4 toxicity according to CTCAE v5.0. - Has a serum phosphorus level > upper limit of normal (ULN) during screening that remains >ULN despite medical management. - Any ocular condition likely to increase the risk of eye toxicity. - History of or current uncontrolled cardiovascular disease. - Active, symptomatic, or untreated brain metastases. - Gastrointestinal disorders that will affect oral administration or absorption of TYRA-200. - Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles
TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.

Locations

Country Name City State
United States The Ohio State University Columbus Ohio
United States The University of Texas MD Anderson Cancer Center Houston Texas
United States University of California San Francisco (UCSF) San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Tyra Biosciences, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase 1 Part A: To determine the maximum tolerated dose (MTD) of TYRA-200. Initiation of study treatment through 28 Days
Primary Phase 1 Part B: To determine the optimal dose of TYRA-200. Initiation of study treatment through 28 days (up to approximately 18 months
Secondary Number of participants with adverse events (AEs) and serious adverse events (SAEs) as a measure of safety and tolerability. From day 1 treatment through 28-days post treatment (up to 2 years)
Secondary Frequency in changes in laboratory parameters and physical signs of toxicity. From day 1 treatment through 28-days post treatment (up to 2 years)
Secondary Pharmacokinetics: maximum plasma concentration (Cmax). From Day 1 through Cycle 3 Day 1 (each cycle is 28 days)
Secondary Pharmacokinetics: time to reach maximum plasma concentration (Tmax). From Day 1 through Cycle 3 Day 1 (each cycle is 28 days)
Secondary Pharmacokinetics: area under the plasma concentration-time curve (AUC). From Day 1 through Cycle 3 Day 1 (each cycle is 28 days)
Secondary Pharmacokinetics: half-life of Tyra-200 (t1/2). From Day 1 through Cycle 3 Day 1 (each cycle is 28 days)
Secondary Overall response rate (ORR) defined as the proportion of participants with complete response (CR) or partial response (PR) as determined by the investigator using RECIST V1.1. From enrollment, every 8 or 12 weeks (up to 2 years)
Secondary Duration of response defined as the time from the initial CR or PR to the time of relapse or death, whichever occurs first among participant with an objective response. From enrollment, every 8 or 12 weeks (up to 5 years)
Secondary Disease control rate defined as the proportion of participants having a CR, PR or stable disease (SD) for >12 weeks. From enrollment up to 5 years
Secondary Time to response defined as time to first CR or PR that is subsequently confirmed according to RECIST v1.1. Up to 5 years
Secondary Progression-free survival defined as the time from the date of first study drug administration to the earliest date of documented disease progression or death. From the date of the first dose of study drug until disease progression or death as assessed up to the last efficacy assessment for disease progression (up to 5 years)
See also
  Status Clinical Trial Phase
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2